Figure 3.
Cumulative incidences of CMV reactivation in the first 100 days post-HCT stratified by the presence of pre-HCT CMV DNAemia. Cumulative incidence curve showing the time to any CMV infection (A,D), to ≥150 IU/mL CMV infection (B,E), or to ≥500 IU/mL CMV infection (C,F), among preemptive therapy (PET)–era patients (n = 1367; A-C) or among participants receiving letermovir (LET) prophylaxis (n = 332; D-F) within the first 100 days after transplant, separated by whether any pretransplant CMV was detected by PCR (yes in red [top line]; no in blue [bottom line]). Lighter colored shading indicates the 95% confidence interval. In each graph, the difference between those with any pretransplant CMV PCR detection was calculated using Gray’s test; associated P values are listed on the right of the graphs.

Cumulative incidences of CMV reactivation in the first 100 days post-HCT stratified by the presence of pre-HCT CMV DNAemia. Cumulative incidence curve showing the time to any CMV infection (A,D), to ≥150 IU/mL CMV infection (B,E), or to ≥500 IU/mL CMV infection (C,F), among preemptive therapy (PET)–era patients (n = 1367; A-C) or among participants receiving letermovir (LET) prophylaxis (n = 332; D-F) within the first 100 days after transplant, separated by whether any pretransplant CMV was detected by PCR (yes in red [top line]; no in blue [bottom line]). Lighter colored shading indicates the 95% confidence interval. In each graph, the difference between those with any pretransplant CMV PCR detection was calculated using Gray’s test; associated P values are listed on the right of the graphs.

Close Modal

or Create an Account

Close Modal
Close Modal